| Description | Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, thereby restoring hemostasis [1]. |
| Synonyms | BI 655075 |
| molecular weight | N/A |
| CAS | 1362509-93-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |